The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: A double blind randomized study

2013 ◽  
Vol 21 (3) ◽  
pp. 164-171 ◽  
Author(s):  
Luis Vitetta ◽  
Samantha Coulson ◽  
Shoshannah L. Beck ◽  
Helen Gramotnev ◽  
Sharon Du ◽  
...  
Keyword(s):  
Whey Protein ◽  
Clinical Efficacy ◽  
Common Cold ◽  
Randomized Study ◽  
Bovine Lactoferrin ◽  
Double Blind ◽  
The Common

Relieving Symptoms of Upper Respiratory Allergies and the Common Cold: Azatadine Maleate/Pseudoephedrine Sulfate Syrup versus Placebo

1983 ◽  
Vol 11 (2) ◽  
pp. 101-107 ◽  
Author(s):  
I Kaminszczik ◽  
L Barbon
Keyword(s):  
Common Cold ◽  
Symptomatic Relief ◽  
Combination Group ◽  
Design Evaluation ◽  
Double Blind ◽  
Test Formulation ◽  
Respiratory Allergies ◽  
The Common ◽  
Upper Respiratory ◽  
Double Blind Design

A total of 132 patients with symptoms associated with either upper respiratory allergies or the common cold was enrolled in this 5-day study. Azatadine maleatelpseudoephedrine sulfate syrup was compared to placebo using a double-blind design. Evaluation of efficacy was based on results in eighty patients and that of safety in 115. Onset of relief was significantly better (p = 0·03) with azatadine maleatel pseudoephedrine sulfate syrup than with placebo. However this was due mainly to the distribution of patients who indicated ‘no relief': ten in the combination group as opposed to sixteen in the placebo group. Over-all evaluation of results indicated that a significantly greater degree of symptomatic relief was achieved with the active test formulation than with placebo on both Days 3 (p = 0·03) and 5 (p = 0·04) of therapy. Somnolence was the most frequently reported side-effect.

scholarly journals Zinc Gluconate and the Common Cold: A Controlled Clinical Study

1992 ◽  
Vol 20 (3) ◽  
pp. 234-246 ◽  
Author(s):  
J C Godfrey ◽  
B Conant Sloane ◽  
D S Smith ◽  
J H Turco ◽  
N Mercer ◽  
...  
Keyword(s):  
Clinical Study ◽  
Common Cold ◽  
Symptom Severity ◽  
Double Blind Trial ◽  
Double Blind ◽  
Zinc Gluconate ◽  
Severity Rating ◽  
The Common ◽  
Controlled Clinical Study ◽  
Efficacy Of Treatment

A report in 1984 on the success of zinc gluconate against common cold symptoms could not be confirmed in three subsequent studies, which are now known to have used formulations that inactivated zinc. A non-chelating formulation including glycine, which releases 93% of contained zinc into saliva, was tested in a randomized, placebo-controlled, double-blind trial in 73 young adults. Efficacy was recorded in symptom diaries using a symptom severity rating. Patients' symptoms first appeared 1.34 days prior to entry to the study in both groups. Disappearance of symptoms occurred after an additional 4.9 days for zinc-treated patients versus 6.1 days for placebo-treated patients. A difference was noted in the efficacy of treatment if it was started 1 day after symptom onset: cold duration was an additional 4.3 days in zinc-treated patients compared with 9.2 days for placebo-treated patients. Cough, nasal drainage and congestion were the symptoms most affected, and only mild side-effects were noted.

Sign in / Sign up

Export Citation Format

Share Document